Updated: Sanofi's $1.5B pact with Teva in IBD adds fuel to anti-TL1A race against Merck, Roivant and Pfizer - Endpoints News
endpts.comSubmitted by endpointsnews6292 in business
Sanofi wasn't the only party interested in Teva's anti-TL1A antibody, but it emerged as the